

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Fujian Haixi Pharmaceuticals Co., Ltd.**  
**福建海西新藥創制股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2637)**

**DATE OF MEETING OF THE BOARD OF DIRECTORS**

The board of directors (the “**Board**”) of Fujian Haixi Pharmaceuticals Co., Ltd. (the “**Company**”, and its subsidiaries, the “**Group**”) announces that a meeting of the Board will be held on Monday, 30 March 2026 for the purposes of considering and approving the annual results of the Group for the year ended 31 December 2025 for publication and transacting any other business, including the recommendation on the payment of a final dividend, if any.

By Order of the Board  
**Fujian Haixi Pharmaceuticals Co., Ltd.**  
**Dr. Kang Xinshan**  
*Chairman and Executive Director*

Fujian, the PRC, 10 March 2026

*As at the date of this announcement, the executive Directors are Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi; the non-executive Directors are Mr. Xu Dong and Mr. Wang Xinkun; and the independent non-executive Directors are Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.*